Premium
The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015
Author(s) -
Jagust William J.,
Landau Susan M.,
Koeppe Robert A.,
Reiman Eric M.,
Chen Kewei,
Mathis Chester A.,
Price Julie C.,
Foster Norman L.,
Wang Angela Y.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.05.001
Subject(s) - neuroimaging , positron emission tomography , alzheimer's disease neuroimaging initiative , medicine , nuclear medicine , standardization , alzheimer's disease , medical physics , psychology , disease , neuroscience , computer science , operating system
This article reviews the work done in the Alzheimer's Disease Neuroimaging Initiative positron emission tomography (ADNI PET) core over the past 5 years, largely concerning techniques, methods, and results related to amyloid imaging in ADNI. Methods The PET Core has used [ 18 F]florbetapir routinely on ADNI participants, with over 1600 scans available for download. Four different laboratories are involved in data analysis, and have examined factors such as longitudinal florbetapir analysis, use of [ 18 F]fluorodeoxyglucose (FDG)‐PET in clinical trials, and relationships between different biomarkers and cognition. Results Converging evidence from the PET Core has indicated that cross‐sectional and longitudinal florbetapir analyses require different reference regions. Studies have also examined the relationship between florbetapir data obtained immediately after injection, which reflects perfusion, and FDG‐PET results. Finally, standardization has included the translation of florbetapir PET data to a centiloid scale. Conclusion The PET Core has demonstrated a variety of methods for the standardization of biomarkers such as florbetapir PET in a multicenter setting.